Curatech

CuraTeQ Biologics is a biopharmaceutical company and a subsidiary of Aurobindo Pharma, focused on the development and commercialization of high-quality biosimilars. Headquartered in Hyderabad, India, the company targets major therapeutic areas including oncology, immunology, and ophthalmology. Its pipeline includes biosimilar versions of blockbuster drugs such as trastuzumab, bevacizumab, and adalimumab, with several products already approved in highly regulated markets like the EU and UK. CuraTeQ operates state-of-the-art R&D and manufacturing facilities that are EU GMP certified, enabling end-to-end production from cell line development to commercial scale. In addition to its internal pipeline, the company has expanded into the CDMO space through strategic partnerships, including a notable agreement with Merck (MSD) to establish manufacturing facilities.